29385237Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TEClinical pharmacology and therapeuticsBreast Neoplasms; Cytochrome P-450 CYP2D6; Pharmacogenetics; TamoxifenAntineoplastic Agents, Hormonal; Cytochrome P-450 CYP2D6 Inhibitors; Female; Genotype; Humans; Neoplasm Recurrence, LocalGoetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018 05; 103(5):770-777.Clin Pharmacol Ther2018-01-31T00:00:002018Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.cmhprofilesont:personsuffixperson suffixFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD009364Disorders17340.980043Neoplasm Recurrence, LocalD010597Occupations141720.851158PharmacogeneticsAuthorship 936110.1632720.1632721authors10.2510has subject areaD013629Chemicals & Drugs110.999185TamoxifenD018931Chemicals & Drugs220.999627Antineoplastic Agents, HormonalD019389Chemicals & Drugs91830.831211Cytochrome P-450 CYP2D61ProfessorD065690Chemicals & Drugs4110.992053Cytochrome P-450 CYP2D6 InhibitorsPediatricsResearchPhD, MSAndreaGaedigkAndrea Gaedigk39.08346750000000-94.577112900000001Gaedigk, Andrea0000-0001-6968-1893Director, Pharmacogenetics Core LaboratoryChildren's Mercy Kansas CityD001943Disorders13420.972127Breast Neoplasmstrue1Director, Pharmacogenetics Core LaboratoryDirector, Pharmacogenetics Core LaboratoryD005260Physiology11835990.534568FemaleD005838Physiology404010.883905GenotypeD006801Living Beings12067970.397999Humans